FDA Alerts

FDA approves first treatment for cerebrotendinous xanthomatosis

The US Food and Drug Administration (FDA) approved Ctexli™ (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. This is the first FDA-approved treatment for CTX, which is a rare lipid storage disease. The approval was based on results from a 24-week, double-blind, placebo-controlled, randomized, crossover study that assessed...